Abstract: The present invention provides methods of treating diseases associated with at least one virus. The methods include administering a compound described in the invention in a therapeutically effective amount. According to some aspects of the present invention, the methods may further comprise at least one immunosuppressant agent to treat diseases associated with at least one virus of a subject in need of immunosuppressant agents.
Type:
Application
Filed:
November 14, 2014
Publication date:
May 21, 2015
Inventors:
George R. Painter, Ernest Randall Lanier, Gwendolyn Painter
Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.
Abstract: The present invention relates to the fields of chemistry and pharmacy and, in particular, to the production of novel molecular entities: esterane derivatives fused with spirostanes rings, acting upon the Central Nervous Systems (CNS). From diosgenin, a naturally occurring sapogenin, with some subsequent transformations thereof, spirosteroid derivatives of the I-IV general formula can be obtained, with a cyclopentaneperhydrophenantrene nucleus fused to a 25R-spirostanes nucleus. Such molecular entities have an anti-inflammatory and anti-glutamatergic actions that can be used to treat inflammatory, cerebrovascular, neurodegenerative, neuropsychiatric, and neurologic diseases.
Type:
Application
Filed:
December 27, 2012
Publication date:
May 21, 2015
Inventors:
Laura Garcia Pupo, Yanier Nuñez Figueredo, Juan Enrique Tacoronte Morales, Yamila Verdecia Reyes, Estael Ochoa Rodriguez, Zaldo Castro Armando
Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
Abstract: A unique combination of weight loss modalities that produce 20-40 pounds of weigh loss in a six week treatment period. Treatment includes a meal plan chosen to provide adequate protein and nutrition during dieting and to assist metabolism of toxins created from the release of stored fat, high amounts of fiber to assist in collecting toxins and fat in the elimination system and to encourage peristaltic action in the bowel, a bowel toner to further increase peristaltic action in the bowel, stimulating liver functions of fat and toxins. The weight loss portion of the treatment is limited to six week segments, and added to the plurality of modalities comprising the invention, to further support the body during weight loss. By supporting the body during weight loss, his invention(s) avoids the “plateau” routinely experienced by existing weight loss systems, when the metabolism slows to avoid further damage from ultra-low calories, medications, bariatric surgeries, and other stressful programs.
Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinsae activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
Type:
Application
Filed:
December 29, 2014
Publication date:
April 30, 2015
Inventors:
Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
Abstract: Pharmaceutical compositions of the invention comprise alkylated imino sugars derivatives having a disease-modifying action in the treatment of diseases associated with glucosidase activity that include Viral hemorrhagic fevers, and any other diseases involving glucosidase activity.
Type:
Application
Filed:
March 27, 2013
Publication date:
April 30, 2015
Inventors:
Yanming Du, Xiaodong Xu, Hong Ye, Jinhong Chang, Timothy M. Block
Abstract: A pesticidal composition comprises a synergistically effective amount of an organophosphate-based acetylcholinesterase (AChE) inhibitor compound and a pesticide selected from N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)thio)propanamide (I), N-(3-chloro-1-(pyridin-3-yl)-1H-pyrazol-4-yl)-N-ethyl-3-((3,3,3-trifluoropropyl)sulfinyl)propanamide (II), or any agriculturally acceptable salt thereof. A method of controlling pests comprises applying the pesticidal composition near a population of pests. A method of protecting a plant from infestation and attack by insects comprises contacting the plant with the synergistic pesticidal composition.
Type:
Application
Filed:
October 17, 2014
Publication date:
April 23, 2015
Inventors:
Luis E. Gomez, Ricky Hunter, Mike Shaw, Tony K. Trullinger, Mary E. Kubiszak
Abstract: A prodrug can have a structure of Formula 10 or derivative thereof or stereoisomer thereof or pharmaceutically acceptable salt thereof. The prodrug can be included in a pharmaceutical composition for use in treatment of fungus, cancer, dermatitis, superficial mycoses; inflammation, tinea pedis, tinea cruris, and tinea corporis, Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis, candidiasis (moniliasis), Candida albicans, tinea (pityriasis) vesicolor, Malassezia furfur, acute myeloid leukemia, acute lymphoid leukemia, chronic myelogenous leukemia, lymphoma or multiple myeloma.
Abstract: Insecticidal compositions suitable for use in preparation of insecticidal liquid fertilizers are disclosed, the compositions comprising bifenthrin, an encapsulated crop protection agent, a hydrated aluminum-magnesium silicate, and at least one dispersant selected from the group consisting of a sucrose ester, a lignosulfonate, an alkylpolyglycoside, a naphthalenesulfonic acid formaldehyde condensate and a phosphate ester.
Type:
Application
Filed:
March 18, 2014
Publication date:
April 9, 2015
Applicant:
FMC Corporation
Inventors:
Timothy M. Martin, William Scherzinger, Margarita Giavis
Abstract: The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.
Abstract: The present invention relates to a composition comprising alfa-lipoic acid, or a salt or complex thereof, and honokiol, wherein the weight quantity of said honokiol is between 1% and 30% with respect to the total weight of honokiol and alfa-lipoic acid.
Abstract: Fungicidal mixtures, comprising as active components 1) at least one 1-methylpyrazol-4-ylcarboxanilide of the formula I where R1?C1-C4-alkyl or C1-C4-haloalkyl, R2=hydrogen or halogen, X=hydrogen or halogen, Q=direct bond, a cyclopropylene or an anellated bicyclo[2.2.
Type:
Application
Filed:
September 29, 2014
Publication date:
March 26, 2015
Inventors:
Markus GEWEHR, Ulf GROEGER, Egon HADEN, Michael VONEND
Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II, and methods for treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Abstract: A strip, which is both edible and dissolvable, is provided comprising a film and a dosage of at least 2% of the reference daily intake (RDI) of at least one dietary supplement for malnutrition or to prevent/treat alcohol induced hangovers. A method for treating malnutrition and/or preventing and treating alcohol-induced hangovers using a dissolvable orally administered strip.
Abstract: The present invention generally concerns particular methods and compositions for antimicrobial therapy. In particular embodiments, the compositions target DXR. In some cases, the antimicrobial agent comprises an electron-deficient hydrophobic group that has interacts with Trp211 of DXR. In specific embodiments, the compound contains electron-deficient heterocyclic rings that specifically interact with the electron-rich indole ring of Trp211. In certain aspects, the compositions comprise a phosphate group, a pyridine group, and a hydroxymate group.
Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
Abstract: Fused aromatic phosphonates of structural formula I are precursors to inhibitors of protein tyrosine phosphatase-1B (PTP-1B). The compounds of the present invention are therefore useful for the treatment in a mammal of a disorder, condition, or disease responsive to inhibition of protein tyrosine phosphatase-1B, including Type 2 diabetes, insulin resistance, a lipid disorder, obesity, Metabolic Syndrome, and cancer.
Type:
Application
Filed:
April 16, 2013
Publication date:
February 26, 2015
Inventors:
Michel Therien, Yves Leblanc, Yongxin Han
Abstract: The present invention relates to bicyclic aryl 1,2,4-oxadiazoles derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.
Type:
Grant
Filed:
September 30, 2013
Date of Patent:
February 17, 2015
Assignee:
Allergan, Inc.
Inventors:
Janet A. Takeuchi, Ling Li, Wha-Bin Im, Ken Chow
Abstract: A method for treating viral infection includes administering to a subject in need thereof a composition containing P2X receptor antagonists. The methods may achieve preventive or therapeutic effect on hand foot and mouth disease by inhibiting viruses. The P2X receptor antagonists can inhibit infection by a positive-sense single-stranded RNA picornavirus. The virus may be an enterovirus or a Coxsackie virus, such as human enterovirus 71. The P2X receptor antagonist may be PPADS, iso-PPADS, PPNDS, Suramin, NF023, TNP-ATP, NF279, NF157, Evans Blue, an analog thereof, a derivative thereof, or a pharmaceutically acceptable salt thereof.
Abstract: The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.
Abstract: Disclosed are compounds of Formula 1, wherein R1 is phenyl or pyridinyl, each optionally substituted with Q and up to 3 substituents independently selected from R2; each R2 is independently halogen, cyano, SF5, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, C1-C4 haloalkoxy, C1-C4 alkylthio or C1-C4 haloalkylthio; and Q is phenyl or pyridinyl, each optionally substituted with up to 5 substituents independently selected from the group consisting of halogen, cyano, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy and C1-C4 haloalkoxy. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.
Abstract: The invention relates to the use of a derivative compound of 1,3-benzodioxole of formula (I) wherein R is a linear or branched (C4-C10) alkyl substituent as a synergistic compound of insecticidal active ingredients insecticidal compositions comprising at least one compound of Formula (I) and at least one insecticidal active ingredient are also described.
Abstract: A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.
Type:
Application
Filed:
July 7, 2010
Publication date:
February 5, 2015
Applicant:
GALEPHAR M/F
Inventors:
Arthur M. Deboeck, Philippe Baudier, Francis Vanderbist, Antonio Sereno
Abstract: Disclosed herein are methods of increasing retinal responsiveness to light in a subject, such as a subject with retinal degeneration. The disclosed methods include administering one or more compounds that decrease or inhibit ?-aminobutyric acid (GABA) signaling to a subject with retinal degeneration. In some embodiments, the methods include selecting a subject with retinal degeneration and administering a ?-aminobutyric acid C (GABAC) receptor antagonist to the subject. In one example, the GABAC receptor antagonist is (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid (TPMPA). In other embodiments, the methods include selecting a subject with retinal degeneration and administering a metabotropic glutamate receptor (mGluR) antagonist to the subject. In one example, the mGluR antagonist is a mGlu1 receptor antagonist (for example, JNJ16259685).
Type:
Application
Filed:
May 17, 2012
Publication date:
February 5, 2015
Applicant:
The United States Government as represented by the Department of Veterans Affairs
Abstract: The present invention describes Photolabile Compounds methods for use of the compounds. The Photolabile Compounds have a photoreleasable ligand, which can be biologically active, and which is photoreleased from the compound upon exposure to light. In some embodiments, the Photolabile Compounds comprise a light antenna, such as a labeling molecule or an active derivative thereof. In one embodiment, the light is visible light, which is not detrimental to the viability of biological samples, such as cells and tissues, in which the released organic molecule is bioactive and can have a therapeutic effect. In another embodiment, the photoreleasable ligand can be a labeling molecule, such as a fluorescent molecule.
Type:
Application
Filed:
December 21, 2012
Publication date:
January 29, 2015
Inventors:
Rafael Yuste, Roberto Etchenique, Luis Baraldo
Abstract: The present invention provides for novel compounds of Formulas I and II and pharmaceutically acceptable salts and co-crystals thereof which have glucokinase activator activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucokinase activator is indicated, including Type 1 and 2 diabetes, impaired glucose tolerance, insulin resistance and hyperglycemia. The present invention also provides for processes of making the compounds of Formulas I and II, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
Type:
Grant
Filed:
May 25, 2011
Date of Patent:
January 27, 2015
Assignee:
Metabasis Therapeutics, Inc.
Inventors:
Feng Tian, Qun Dang, G. Sridhar Prasad, Wenyu Li, Brett C. Bookser, Nicholas Brian Raffaele, Mark D. Erion
Abstract: The present invention provides compositions comprising sugar, cysteine, and/or sugar-cysteine products, methods of preparing the same, and/or using the same.
Type:
Application
Filed:
October 6, 2014
Publication date:
January 22, 2015
Inventors:
David Bagley, Scott Momii, Scott Nagasawa, Herbert T. Nagasawa
Abstract: The present invention provides a compound having a muscle cell or adipocyte differentiation regulating action, useful for the prophylaxis or treatment of diseases such as diabetes, obesity, dyslipidemia and the like, and the like, and having superior efficacy. The present invention provides a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof.
Abstract: A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement.
Type:
Application
Filed:
July 28, 2014
Publication date:
January 15, 2015
Inventors:
Jacqueline M. Hibbert, Jonathan K. Stiles, Kayellen Umeakunne, Hyacinth I. Hyacinth
Abstract: The present invention provides targeted delivery compositions and methods of using the compositions for treating and diagnosing a disease state in a subject.
Abstract: A mixed metal complex of a compound of Formula I, or a salt thereof, wherein the mixed metals comprise a Group III-XII transition metal and a Group II metal: (Formula I) (I) wherein X, R1, R2, R3, and R4 are as defined herein, is produced in a one step crystallization from a solution of the Group III-XII transition metal, the Group II metal, and a compound of Formula I. Methods for treatment of a pathological condition in a patient, for example, a pathological condition caused by the presence of oxygen-derived free radicals, comprises administering the mixed metal complex to the patient.
Type:
Application
Filed:
December 4, 2012
Publication date:
January 1, 2015
Inventors:
Jan-Olof Karlsson, Karl Reineke, Tino Kurz, Rolf Andersson, Michael Hall, Christina McLaughlin, Sven Jacobsson, Jacques Nasstrom
Abstract: This invention relates to the use of cyclopropylamine derivatives for the modulation, notably the inhibition of the activity of Lysine-specific demethylase 1 (LSD1). Suitably, the present invention relates to the use of cyclopropylamines in the treatment of cancer.
Type:
Application
Filed:
September 3, 2014
Publication date:
December 18, 2014
Inventors:
Neil W. Johnson, Jiri Kasparec, Meagan B. Rouse, Xinrong Tian
Abstract: Insecticide formulations having improved chemical and physical stability and related methods are disclosed. The insecticide formulations may include a plurality of microcapsules, each including at least one organophosphate insecticide (e.g., chlorpyrifos-methyl) at least partially surrounded by a polymer shell. The insecticide formulations may be used to control insect populations by singular or periodic applications. The microcapsule polymer shell of the insecticide formulations may be formed by combining a cross-linking amine and a hydrophobic monomer (e.g., an isocyanate) at a molar ratio of amine to isocyanate groups of less than about 1:1.
Type:
Grant
Filed:
February 10, 2012
Date of Patent:
December 16, 2014
Assignee:
Dow AgroSciences, LLC.
Inventors:
Dennis G. Wujek, Raymond E. Boucher, Jr., Martin C. Logan, Stephen L. Wilson, Mei Li, Lorenzo Aulisa
Abstract: The present application discloses compounds of formula (I) wherein X is ?O, ?S, ?NH, ?NOH and ?NO-Me; A is —C(?O)—, —S(?O)2—, —C(?S)— and P(?O)(R5)—; B is, —O—, —(CH2)3-6—, and O—(CH2)2-5—; D is, —O—, —CR7R8— and —NR9; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R1 is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.
Type:
Application
Filed:
August 18, 2014
Publication date:
December 4, 2014
Inventors:
Mette Knak CHRISTENSEN, Fredrik BJORKLING
Abstract: The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
Type:
Application
Filed:
December 10, 2012
Publication date:
November 27, 2014
Applicant:
Viamet Pharmaceuticals, Inc
Inventors:
William J. Hoekstra, Christopher M. Yates
Abstract: The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.
Type:
Grant
Filed:
December 21, 2012
Date of Patent:
November 25, 2014
Assignee:
Abbott Cardiovascular Systems Inc.
Inventors:
Stephen D. Pacetti, Paul M. Consigny, Ronald W. Heil, Jr., Florian Niklas Ludwig, Dariush Davalian, Li Zhao, Irina Astafieva, Jinping Wan, Fozan El-Nounou, Katsuyuki Murase, Syed F. A. Hossainy, Rachel Bright, Jeffrey Ellis
Abstract: The invention relates to nitroso derivatives including carboxylic acid and phosphoric acid esters of hydroxy nitroso compounds that donate nitroxyl (HNO) under physiological conditions. The compounds and compositions of the invention are useful in treating and/or preventing the onset and/or development of diseases or conditions that are responsive to nitroxyl therapy, including heart failure, ischemia/reperfusion injury and cancer.
Type:
Application
Filed:
July 28, 2014
Publication date:
November 13, 2014
Inventors:
Lisa Marie Frost, Stephen Martin Courtney, Frederick Arthur Brookfield, Vincent Jacob Kalish
Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.
Abstract: The invention provides certain amino-pyridine-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and n are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.
Type:
Application
Filed:
July 10, 2014
Publication date:
October 30, 2014
Inventors:
Eric Thomas Miller, Michelle R. Machacek, Benjamin Wesley Trotter, Thomas Allen Miller, Brian Michael Andresen, Neville John Anthony, Brandon M. Taoka, Yuan Liu
Abstract: The invention relates to novel insecticidal active compound combinations comprising, firstly, anthranilamides (group 1) and, secondly, further insecticidal active compounds selected from the group of the (thio)phosphates (group 2) and/or the group of the carbamates (group 3), which combinations are highly suitable for controlling animal pests, such as insects.
Type:
Grant
Filed:
June 9, 2010
Date of Patent:
October 21, 2014
Assignee:
Bayer CropScience AG
Inventors:
Christian Funke, Reiner Fischer, Rüdiger Fischer, Heike Hungenberg, Wolfram Andersch, Wolfgang Thielert, Anton Kraus
Abstract: The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analogue or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.
Type:
Application
Filed:
November 14, 2012
Publication date:
October 2, 2014
Inventors:
Kenneth W. Lyles, Cathleen S. Colon-Emeric, Christopher M. O'Connor, Dennis Abraham, Kent Nilson, Howard Rockman, Graham Russell
Abstract: The present invention relates to novel active compound combinations comprising, firstly, at least one known compound of the formula (I) in which R1 and A have the meanings given in the description and, secondly, at least one further known active compound from the class of the organophosphates or carbamates, which combinations are highly suitable for controlling animal pests such as insects and unwanted acarids.
Type:
Grant
Filed:
March 25, 2009
Date of Patent:
September 30, 2014
Assignee:
Bayer CropScience AG
Inventors:
Heike Hungenberg, Peter Jeschke, Robert Velten, Wolfgang Thielert
Abstract: A water dispersible granule composition comprising microcapsules comprising at least one agrochemical active ingredient encapsulated within a urea formaldehyde polymeric shell wall, at least one inert filler and at least one agrochemical excipients.
Abstract: A one pack aqueous insecticidal architectural coating composition comprising an aqueous dispersion of polymer particles as binder and further comprising, based on the total liquid paint formulation, i) from 0.1 to 4.0 wt % insecticide; ii) from 0.5 to 6.5 wt % dibasic ester solvent wherein the insecticide is located in the polymer particles and the polymer particles are film forming at ambient temperatures.
Type:
Application
Filed:
October 29, 2012
Publication date:
September 25, 2014
Inventors:
Kai Kang, Junbiao Lu, Daragh McLoughlin, Jørgen H. Olsen